Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
Annexon (Nasdaq: ANNX) said it will present Phase 2 ARCHER analyses at ASRS 2026 on vonaprument in geographic atrophy (dry AMD). The talk will cover baseline factors linked to confirmed BCVA 15-letter loss, to guide patient selection for Phase 3 ARCHER II (659 patients). Topline data are expected in Q4 2026.
How this was made
The 30-second read
Why it matters
The ASRS presentation is positioned to refine patient population selection for ARCHER II, potentially improving the probability of demonstrating BCVA 15-letter loss benefit at the primary endpoint.
Market read
This is a pre-topline conference update that may modestly support confidence in ARCHER II execution, but it does not introduce new trial results.
What to watch
Investors may focus more on whether ARCHER II’s primary endpoint design and patient enrichment actually reduce variability, rather than on retrospective baseline associations.
Background
Annexon’s vonaprument (formerly ANX007) is in Phase 3 ARCHER II after a completed Phase 2 ARCHER trial in geographic atrophy (GA) from dry AMD.
Ticker impact
Annexon (ANNX) will present Phase 2 ARCHER baseline factors tied to BCVA 15-letter loss, informing patient selection for Phase 3 ARCHER II with topline expected Q4 2026.
Near-term impact likely limited until ARCHER II topline in Q4 2026, though sentiment could improve ahead of ASRS.
The article discloses no new efficacy/safety datapoints, only that baseline characteristics will be highlighted; the most decision-relevant catalyst remains the Phase 3 topline timing.
Market effects
Supports ongoing investor focus on complement-targeting neuroprotective approaches for dry AMD geographic atrophy.
Minimal, as the catalyst is a US-listed biotech conference update.
Moderate, given PRIME/Fast Track designations and a global Phase 3 registration path with US and European regulators.
Counterpoint
Baseline-characteristic analyses may not translate into improved Phase 3 outcomes, so the market may discount the incremental signal.
Key entities
- companyAnnexon, Inc.
Nasdaq-listed biopharmaceutical advancing vonaprument for geographic atrophy (GA) in dry AMD.
- drug_candidatevonaprument
Intravitreal antigen-binding fragment designed to block C1q and the classical complement pathway.
- clinical_trialPhase 2 ARCHER
Completed Phase 2 trial in GA; showed vision preservation and protection of retinal structures.
- clinical_trialPhase 3 ARCHER II
Ongoing pivotal Phase 3 sham-controlled trial; enrollment completed July 2025; topline expected Q4 2026.
- eventASRS 44th Annual Scientific Meeting
Conference where Annexon will present baseline characteristics associated with BCVA loss.
